Applying radiobiological principles to combined modality treatment of head and neck cancer - The time factor

被引:101
作者
Peters, LJ [1 ]
Withers, HR [1 ]
机构
[1] UNIV CALIF LOS ANGELES,DEPT RADIAT ONCOL,LOS ANGELES,CA 90024
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 39卷 / 04期
关键词
head and neck cancer; time factor; tumor cell regeneration; combined modality treatment; protocol optimization;
D O I
10.1016/S0360-3016(97)00466-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Combined modality treatment is indicated for most advanced stage head and neck cancers, It is postulated that the efficacy of combined modality regimens could be enhanced by applying principles derived from radiotherapy fractionation studies to optimize the time factor in treatment scheduling. Methods and Materials: The premise that tumor clonogens surviving a therapeutic intervention undergo accelerated repopulation in a time-dependent fashion as their numbers are depleted is used as a model to interpret the results of various chemoradiotherapy and postsurgical radiotherapy protocols and to suggest ways in which future combined modality regimens can be more rationally designed. Results: Meta-analyses of chemoradiotherapy trials show the general superiority of concomitant vs. neoadjuvant sequential protocols, There is also emerging evidence that both the duration of postoperative radiotherapy and the delay in its instigation affect treatment outcome, These results are compatible with the hypothesis that the overall duration of the ''package deal'' of combined modality treatment is an important determinant of outcome, However, a large decrease in duration of the ''package deal'' does not necessarily translate into a therapeutic gain because the total dose has to be lowered to prevent intolerable acute reactions, In these circumstances tumor control will improve only if the reduced treatment time circumvents more tumor cell regeneration than the cytoreduction that could be achieved by the extra dose tolerable in a longer time period, More modest reductions in treatment time can be accomplished without dose reduction and so avoid this risk, The design of new protocols should take account of the fact that regeneration of tumor clonogens can be predicted to be nonuniform with time, Thus, the greatest therapeutic gain should be achieved by targeting periods of maximal regenerative capacity for shortening or, alternatively, for intensification of treatment, These periods are the latter part of a course of radiotherapy or chemotherapy and the early postoperative phase after surgery. Conclusions: The rational design of combined modality protocols should include principles concerning the time factor derived from radiotherapy fractionation studies, Periods of maximal tumor cell regeneration should be targeted for shortening or for treatment intensification, Any dose sacrifice necessitated by reducing treatment duration must be less than the dose equivalent of regeneration during the same time period. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:831 / 836
页数:6
相关论文
共 31 条
[1]  
ANG KK, IN PRESS P 4 INT C H
[2]   ACCELERATED VERSUS CONVENTIONAL FRACTIONATION IN THE POSTOPERATIVE IRRADIATION OF LOCALLY ADVANCED HEAD AND NECK-CANCER - INFLUENCE OF TUMOR PROLIFERATION [J].
AWWAD, HK ;
KHAFAGY, Y ;
BARSOUM, M ;
EZZAT, S ;
ELATTAR, I ;
FARAG, H ;
AKOUSH, H ;
MEABID, H ;
ZAGHLOUL, MS .
RADIOTHERAPY AND ONCOLOGY, 1992, 25 (04) :261-266
[3]   RESECTION OF ADVANCED CERVICAL METASTASIS PRIOR TO DEFINITIVE RADIOTHERAPY FOR PRIMARY SQUAMOUS CARCINOMAS OF THE UPPER AERODIGESTIVE TRACT [J].
BYERS, RM ;
CLAYMAN, GL ;
GUILLAMONDEQUI, OM ;
PETERS, LJ ;
GOEPFERT, H .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1992, 14 (02) :133-138
[4]  
CUMMINGS BJ, 1996, P 15 ANN ESTRO M
[5]  
DATTA N R, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P132
[6]  
*DEP VET AFF LAR C, 1991, NEW ENGL J MED, V324, P1685
[7]   OVERVIEW OF COMBINED MODALITY THERAPIES FOR HEAD AND NECK-CANCER [J].
DIMERY, IW ;
HONG, WK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (02) :95-111
[8]   Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials [J].
ElSayed, S ;
Nelson, N .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :838-847
[9]   HYPERFRACTIONATION VERSUS CONVENTIONAL FRACTIONATION IN OROPHARYNGEAL CARCINOMA - FINAL ANALYSIS OF A RANDOMIZED TRIAL OF THE EORTC COOPERATIVE GROUP OF RADIOTHERAPY [J].
HORIOT, JC ;
LEFUR, R ;
NGUYEN, T ;
CHENAL, C ;
SCHRAUB, S ;
ALFONSI, S ;
GARDANI, G ;
VANDENBOGAERT, W ;
DANCZAK, S ;
BOLLA, M ;
VANGLABBEKE, M ;
DEPAUW, M .
RADIOTHERAPY AND ONCOLOGY, 1992, 25 (04) :231-241
[10]  
HORIOT JC, IN PRESS EU J CANC